医薬品製造におけるESG（環境・社会・ガバナンス）調査 - 持続可能なサプライチェーンに向けて

当レポートは、医薬品製造におけるESG（環境・社会・ガバナンス）について調査し、医薬品製造が自然界や社会にどのような影響を与えているのか、また、現在の医薬品製造はどの程度持続可能なのか、といったESGの観点から医薬品サプライチェーンについて考察しています。

目次

• エグゼクティブサマリー
• 目的、設計、調査手法
• 当社のESGフレームワーク
• サステナビリティ優先順位のランク付け
• 環境の持続可能性：製薬業界は十分に取り組んでいますか？
• 課題と解決策
• 社会的持続可能性：不足と強力なサプライチェーン
• 変更の実施

付録

• 略語
• 関連レポート
• 著者について
• テーマ調査手法

This report analyzes the Chinese manufacturing industry, including company and facility trends, as well as drug approval and outsourcing trends. It assesses which foreign and domestic pharma manufacturing companies have the largest number of facilities in China, their manufacturing capabilities, which CMOs have secured the largest number of contracts for FDA and EMA approved products and quantifies the level of M&A activity for Chinese pharma

Sustainability, referred to as environmental, social, and governance (ESG), is one of the most important themes for today and the coming decades. Worldwide, the public is demanding action and public accountability from industry.

This reports examines the pharmaceutical supply chain through the lens of ESG: In what ways does pharmaceutical manufacturing impact the natural world and society? How sustainable are its current practices? With what goals and methods can the industry improve its sustainability?

Scope

This 45-page report gives important, expert insight you won't find in any other source. 23 figures and graphics throughout the report illustrate major points and trends. This report is required reading for -

• CMO executives and strategic decision-makers: improves understanding of the pharma manufacturing industry and is a critical input for strategic ESG planning efforts.
• Sourcing and procurement executives in bio/pharmaceutical companies: improving understanding of crucial components of the supply base that will provide insights for supplier selection and management.
• Investors: they can gain a deeper understanding of the pharma manufacturing industry and the forces driving change.

Reasons to Buy

ESG should not be an exercise in corporate "greenwashing", and this report is a realistic look at pharma industry actions and values. We assess industry willingness to change, and pragmatic motivations that can influence company behavior.

GlobalData ran six polls on its Verdict network of B2B websites -

Q1: What is the most important sustainability area that the pharma industry needs to address?

Q2: Do you think that the pharma industry is doing enough to be more environmentally sustainable?

Q3: What is the main challenge to pharmaceutical companies achieving sustainable manufacturing?

Q4: How can the pharmaceutical industry best reduce its damage to the environment (end-of-pipe actions)?

Q5: How can the pharmaceutical industry best reduce its damage to the environment (pre-/post-manufacturing actions)?

Q6: What factors can motivate the pharma industry to improve its environmental, social, and governance actions?

Table of Contents

Table of Contents

• Executive Summary
• Objectives, Design & Methodology
• Our ESG Framework
• Ranking Sustainability Priorities
• Environmental Sustainability: Is the Pharma Industry Doing Enough?
• Challenges and Solutions
• Social Sustainability: Shortages & Strong Supply Chains
• Implementing Change

Appendix

• Abbreviations
• Related Reports
• About the Authors
• Our thematic research methodology